Modern Evaluation and Treatment of Malignant Pancreatic, Liver and Biliary Tract Tumours
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: closed (20 December 2023) | Viewed by 6192
Special Issue Editor
Interests: pancreatic ductal adenocarcinoma; pancreatic cystic tumours; biliary tract cancers; liver metastases; hepatocellular carcinoma (HCC); neuroendocrine tumours; surgical oncology; hepatopancreatobiliary surgery; tumour biology; microRNAs; exosomes; noncoding RNAs; biomarkers; RNA sequencing; liver regeneration
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic ductal adenocarcinoma (PDAC) and liver and biliary tract tumours (including ampullary cancer, gallbladder cancer, and cholangiocarcinoma) are aggressive malignancies. Most patients present with advanced disease due to late diagnosis, and as there are few effective therapeutic options, outcomes are extremely poor.
To improve survival, efforts must be multifaceted and focus on prevention, early identification of high-risk individuals, and prompt diagnosis, as well as molecular-based targeted therapies for established disease. Therefore, a better understanding of their genetic landscape, crucial aspects of tumour biology implicated in disease development and progression, and the identification of diagnostic, predictive, and prognostic biomarkers are extremely important.
While the evolution of precision medicine in recent decades has changed the treatment landscape in many cancers, at present, no targeted therapies are used routinely in the management of these tumours. However, crucial genetic changes have been identified, and these will hopefully lead to a more personalised approach.
In this Special Issue, we are inviting original research articles, reviews, and perspectives to address some of these challenges for these tumours. Topics will include but are not limited to the biology and genomic characteristics of these cancers; the coding and non-coding transcriptome; the role of extracellular vesicles; biomarkers in tissue, blood, and biofluids; “liquid biopsies”; the identification of novel therapeutic targets; and new surgical/oncological/radiological approaches for treating localized and more advanced disease.
We look forward to receiving your contributions.
Dr. Adam Frampton
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiology
- medical oncology
- interventional radiology
- endovascular procedures
- liver neoplasms
- computer-assisted image processing
- deep learning
- pancreatic ductal adenocarcinoma
- biliary tract cancers
- ampullary cancer
- gallbladder cancer
- cholangiocarcinoma
- pancreatic neuroendocrine tumours
- tumour biology
- exosomes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
